Overview

A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the clinical effective dose of KRN321 administered with once triweekly schedule.
Phase:
Phase 2
Details
Lead Sponsor:
Kyowa Hakko Kirin Company, Limited
Kyowa Kirin Co., Ltd.
Treatments:
Darbepoetin alfa